NEW YORK, Sept. 3, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today issued a shareholder update highlighting strategic progress, robust market tailwinds, and accelerating growth opportunities. The full shareholder letter may be read HERE. DarioHealth Corporate Contacts: DarioHealth Investor Relations Contact Michael Lipari SVP Corporate Development [email protected] +1-201-785-6310 Zoe Harrison VP, Accounting and Corporate ...

Berkeley, Calif, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (NASDAQ: PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual’s biochemistry, announces that Ben Hwang, Ph.D., Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 27th Annual Global Investment Conference. The conference is being held on September 8 – 10, 2025 at the Lotte New York Pal ...

BEIJING, Sept. 2, 2025 /PRNewswire/ -- CIMG Inc. ("CIMG" or the "Company") (Nasdaq: IMG), a business group specializing in digital health and sales development, which utilizes technology and marketing to enhance its partners' sales growth and commercial value, today announced that on September 2, 2025, it closed the previously announced sale of sale of 220 million shares of its common stock at $0.25 per share for gross proceeds of $55,000,000 in exchange for 500 Bitcoin. The Board of Directors of CIMG Inc. ...

Back-to-School Season Just Got Smarter The Pediatric Health Assessment empowers parents and providers to uncover hidden health or behavioral issues that may affect academic and social success. QHSLab’s platform delivers critical insights at the perfect time for pediatricians to support whole-child wellness as families prepare for the new academic year. West Palm Beach, FL, Sept. 02, 2025 (GLOBE NEWSWIRE) -- QHSLab Inc. (the “Company”) (OTCQB: USAQ), a leading provider in digital medicine solutions for prima ...

Pipeline of commercial opportunities increases to $67 million NEW YORK, Sept. 2, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today announced the launch of five new contracts with self-insured employers. All five programs went live during the second and third quarters of 2025 and feature Dario's full cardiometabolic suite, highlighting continued demand for integrated, multi-condition solutions. "We believe that employer contr ...

Core Insights - Rocket Doctor AI Inc. reported its first significant revenue quarter in Q2 2025, generating $0.5 million, primarily due to the acquisition of Rocket Doctor Inc. [5][6] - The company completed the acquisition of Rocket Doctor Inc. on April 10, 2025, enhancing its digital health platform and expanding its operational capabilities [4][12] - The company is focusing on U.S. expansion and has secured new contracts, including a virtual-care partnership with Central California Alliance for Health, serving approximately 450,000 members [5][23] Financial Highlights - Q2 2025 revenue was $0.5 million, compared to $0 in Q1 2025 and Q2 2024, marking a significant increase attributed to the Rocket Doctor acquisition [6] - Gross margin for Q2 2025 was 89%, a notable improvement from 0% in previous quarters, driven by revenue from the digital health platform [6][27] - The net comprehensive loss for Q2 2025 was $2.7 million, or $0.04 per share, consistent with the loss reported in Q1 2025 but an improvement from $2.7 million or $0.07 per share in Q2 2024 [6][27] Corporate Developments - The company has shifted its business model from B2C to B2B, aligning with the demand for AI-driven solutions in healthcare systems and academic institutions [8] - The Global Library of Medicine (GLM) is central to the company's strategy, providing clinical decision support and educational tools [7][21] - The company has made significant investments in enhancing its platform architecture and API capabilities, positioning itself for accelerated commercialization [24] Market Opportunity - The global AI healthcare market is projected to exceed USD $180 billion by 2030, driven by the demand for efficiency and accuracy in clinical workflows [9] - The conversational AI segment is expected to grow from approximately USD $13.5 billion in 2024 to between USD $49 billion and $123 billion by 2030, indicating a ~24% CAGR [9] Product Development - The Medical Education Suite (MES) was successfully deployed to 240 medical students at the University of Minnesota, showcasing the potential of AI-driven tools in medical education [15][24] - Rocket Doctor's technology solutions, including Starship EMR and RD Connect, are designed to streamline workflows and reduce care delivery costs [12][19] - The company is actively developing an AI Pharmacy Assistant, with integration plans involving over 20 pharmacies [18]

Key Takeaways HIMS adds Europe via ZAVA acquisition, eyes Canada in 2026 with weight-loss-focused expansion.HIMS hit 2.4 million subscribers in Q2 2025, with 30.8% year-over-year growth and rising per-user revenue.AMWL boosts software to 57.1% of revenue, aided by its MHS contract expansion.Virtual healthcare is rapidly evolving, with Hims & Hers Health, Inc. (HIMS) and American Well Corporation (AMWL) , popularly known as Amwell, at the forefront. HIMS is a consumer-focused digital health platform that off ...

Led by Prof. Dr. Marianne Brodmann, PI of clinical studies for the Lumee™ Oxygen CE Mark, collaboration includes practice adoption and platform integration in cases and clinical study programs BERKELEY, Calif, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual’s biochemistry, announces a commercial and clinical collabora ...

Core Viewpoint - PAVmed Inc. has formed a new subsidiary to license advanced endoscopic imaging technology from Duke University, aimed at improving the diagnosis and treatment of esophageal dysplasia, which is a precursor to esophageal cancer [1][8]. Group 1: Technology and Collaboration - The technology involves a multi-modality probe that combines angle-resolved low coherence interferometry (a/LCI) with optical coherence tomography (OCT), potentially offering a more efficient alternative to traditional biopsies [1]. - PAVmed will collaborate with Lucid Diagnostics as a strategic and equity partner in this initiative [1]. - The technology is expected to enable real-time detection and immediate treatment of dysplasia during endoscopic procedures, addressing the limitations of traditional biopsy methods [3][6]. Group 2: Clinical Implications - Dr. Nicholas Shaheen highlighted that this technology could transform the diagnosis and treatment of esophageal precancer, improving patient outcomes and healthcare resource utilization [2]. - Prior clinical research indicated that the a/LCI technology demonstrated 100% sensitivity and 88% overall accuracy in detecting precancerous changes during live examinations [6]. - The integrated a/LCI and OCT technology has shown comparable sensitivity and improved specificity for detecting dysplasia, with results pending peer-reviewed publication [6]. Group 3: Company Strategy and Market Potential - PAVmed's CEO, Dr. Lishan Aklog, expressed optimism about the commercialization of this technology, anticipating that widespread adoption will significantly increase the diagnosis of esophageal precancer [7]. - The venture aligns with PAVmed's structure of independently financeable subsidiaries and builds on successful partnerships with academic medical centers [8]. - The exclusive worldwide license agreement for the a/LCI + OCT technology is contingent upon the execution of a definitive license agreement [8].

NEW YORK, Aug. 25, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today announced that a reverse stock split of the Company's issued and outstanding common stock, par value $0.0001 per share (the "Common Stock") at a ratio of 20-for-1 is expected to be implemented at market open on August 28, 2025. The Company's Common Stock will begin trading on the Nasdaq Capital Market on a post-split basis at the market open on August 28, 2 ...